Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Pharmaceuticals & Biotech
Create a narrative
Biovica International Community
OM:BIOVIC B Community
2
Narratives
written by author
0
Comments
on narratives written by author
11
Fair Values set
on narratives written by author
Community Investing Ideas
Biovica International
Popular
Undervalued
Overvalued
Biovica International
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Growing Cancer Incidence And AI Will Drive Diagnostic Expansion
Key Takeaways Success in clinical trials and partnerships could accelerate adoption of DiviTum, driving rapid sales growth, recurring revenues, and higher gross margins through scalability and digital integration. Biovica's unique diagnostic position in value-based healthcare and precision oncology enhances its potential for durable premium pricing, industry consolidation, and attractiveness as an acquisition target.
View narrative
SEK 3.00
FV
78.5% undervalued
intrinsic discount
218.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Biovica International
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
DiviTum Entry Will Expand Breast Cancer Treatment Opportunities
Key Takeaways Biovica's strategic partnerships and agreements are expected to expand market penetration, potentially boosting sales and future revenue growth. New clinical trial data and collaborations may enhance adoption of DiviTum, improving revenue streams and profit margins.
View narrative
SEK 1.80
FV
64.1% undervalued
intrinsic discount
204.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
Your Valuation for
BIOVIC B
BIOVIC B
Biovica International
Your Fair Value
SEK
Current Price
SEK 0.65
64.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-173m
131m
2015
2018
2021
2024
2025
2027
2030
Revenue SEK 130.9m
Earnings SEK 27.3m
Advanced
Set Fair Value